Mylan Pharmaceuticals has introduced Norethindrone Tablets USP, 0.35mg, which is the generic version of Watson Laboratories' (now Actavis) Nor-Q.D. tablets, 0.35mg for 28-day cycle, for the prevention of pregnancy in the US.
The abbreviated new drug application (ANDA) of Norethindrone Tablets USP, 0.35mg was granted final FDA approval to Mylan's partner, Famy Care.
US sales for Norethindrone Tablets USP, 0.35 mg for the 12 months ending on 31 March 2013 was approximately $39m, according to IMS Health.
Mylan is a global pharmaceutical company offering a portfolio of approximately 1,100 generic pharmaceuticals and several brand medications besides a range of antiretroviral therapies.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/mylan-introduces-new-generic-contraceptive-pill-in-us-170713
